Melbourne (Australia) – 16 February 2022. Telix announces a commercial distribution agreement with Global Medical Solutions Australia (GMSA), for Illuccix® in the Australian market
Telix is pleased to announce that it has entered into a commercial distribution agreement with Global Medical Solutions Australia (GMSA), for Telix’s prostate cancer imaging product Illuccix® (Kit for the preparation of 68Ga-PSMA-11) for the Australian market.
GMSA is a global manufacturer and distributor of diagnostic and therapeutic radiopharmaceuticals which owns and operates 16 radiopharmacies through the Asia Pacific region.
The distribution agreement significantly expands patient access to Illuccix, which will now be available to every PET/CT site across Australia via GSMA, who will distribute Illuccix kits as well as 68Ga-PSMA-11 unit doses from its network of six radiopharmacies across the country.
Illuccix is the first regulatory approved PET agent for the diagnostic imaging of men with prostate cancer available in Australia, having received marketing approval from the Australian Therapeutic Goods Administration (TGA) in November 2021. Australia has one of the highest rates of prostate cancer in the world. In 2020, prostate cancer was the most commonly diagnosed cancer in men in Australia with approximately 18,000 new cases.
CEO Telix Asia Pacific, Dr. David Cade stated, “We are pleased to have entered this commercial distribution agreement with GMSA, thus delivering a key component of Telix’s supply chain strategy in Australia, our home market. This builds on the clinical supply agreement signed in April last year, which has enabled the manufacturing and supply of finished unit doses for Telix’s CUPID and ProstACT studies of TLX592 and TLX591, respectively. GMSA has built an extensive nuclear pharmacy distribution network in Australia, through which we will deliver broad equity of access to state-of-the-art imaging for all Australian men living with prostate cancer. This includes men living in regional and rural Australia, where access to advanced prostate cancer imaging has traditionally been poor.”
GMS Senior Vice President Operations and Business Development, Shahe Bagerdjian added, “We are delighted to be expanding our partnership with Telix and we look forward to bringing Illuccix® and patient-specific 68Ga-PSMA-11-unit doses to Australian men in need through our market-leading radiopharmacy network. This commercial partnership with Telix opens the door to the new standard of care in prostate cancer imaging for the 18,000 men diagnosed with prostate cancer each year in Australia.”
The initial term of the Agreement is for a period of five years. The agreement is subject to industry standard commercial performance and termination conditions.